The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS. 120 patients were enrolled into two groups respectively, the experimental group and reference group.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
take advantage of RFA to destroy hepatocellular carcinoma by high temperature
the Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
RECRUITINGProgression-free survival
Time from patients received treatment fist time to disease progress or death
Time frame: through study completion, an average of 4 years
Objective response rate
The ratio of patients with regressive disease ,including complete response and partial response
Time frame: through study completion, an average of 4 years
Disease control rate
The ratio of patients with regressive or stable disease, including complete response, partial response and stable disease.
Time frame: through study completion, an average of 4 years
Overall survival
Time from the random assignment to death (the last follow-up time for patients lost to follow-up, the end of study for patients still alive
Time frame: through study completion, an average of 4 years
Duration of response
Time from the first time of complete regression or partial regression to progressive disease or death
Time frame: through study completion, an average of 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.